Tempus AI

TEM

Market cap $16B

Tempus AI NASDAQ: TEM has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a whopping 155% on Monday, Oct. 13.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. “We're sharing research at ESMO Congress 2025, including two oral presentations, that highlight the growing role of real-world data and AI in developing more effective, personali.

Tempus AI deepens its collaboration with Northwestern Medicine, embedding its AI co-pilot David directly into the health system's EHR to boost clinical efficiency.

Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency's ADAPT (Advanced Analysis for Precision Cancer Therapy) program. The ADAPT program aims to revolutioni.

Tempus AI Inc (NASDAQ:TEM) has become one of 2025's most dramatic comeback stories. The stock soared past $100 this week, marking a new 52-week high and sending the market buzzing about the AI-powered cancer diagnostics company's growth prospects.

Short interest is a powerful market force that can not only cap gains but drive share prices lower, but not always. Sometimes, even the short sellers get things wrong.

What a difference a week can make on the stock market. Next-generation healthcare tech company Tempus AI's (TEM 1.56%) stock was doing quite well, thank you very much, over the past few days, in contrast to the preceding five-day trading stretch.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution.

Artificial intelligence (AI) is transforming the world in much the same way as the adoption of the internet did 30 years ago. This is about more than just search; AI is changing the way many industries handle administrative tasks.